Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Editorial Expression of Concern: Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
Journal: British journal of cancer
Published: October 06, 2025
Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype.
Journal: Cancer chemotherapy and pharmacology
Published: December 27, 2023
A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors.
Journal: American journal of clinical oncology
Published: June 02, 2023
A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.
Journal: Cancer chemotherapy and pharmacology
Published: May 17, 2023
Carboplatin-induced upregulation of pan β-tubulin and class III β-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancer.
Journal: Cellular and molecular life sciences : CMLS
Published: April 24, 2023
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: June 09, 2022
Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cells.
Journal: Cancer drug resistance (Alhambra, Calif.)
Published: January 01, 2020
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 28, 2019
Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the Ovarian Data Set From The Cancer Genome Atlas.
Journal: JCO clinical cancer informatics
Published: January 18, 2019
The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Journal: PloS one
Published: August 09, 2018
A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.
Journal: Cancer chemotherapy and pharmacology
Published: May 10, 2018
Last Updated: 09/26/2026